POINT Biopharma Global Inc. (NASDAQ:PNT) Given Consensus Recommendation of “Hold” by Brokerages

POINT Biopharma Global Inc. (NASDAQ:PNT – Get Free Report) has earned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation. The average twelve-month target price among brokerages that have covered the stock in the […]

Leave a Reply

Your email address will not be published.

Previous post PagSeguro Digital Ltd. (NYSE:PAGS) Receives $12.32 Consensus PT from Analysts
Next post Analysts Set Traeger, Inc. (NYSE:COOK) Price Target at $4.95